文献速递妇科生殖医学

基于电子健康记录的多囊卵巢综合征全基因组关联研究

A genome-wide association study of polycystic ovary syndrome identified from electronic health records.
PubMed 文献 · Am J Obstet Gynecol · 2020-04-11

该研究基于鹿特丹标准开发了多囊卵巢综合征(PCOS)表型算法,从三个电子健康记录生物库中识别病例和对照,进行发现-验证全基因组关联研究。发现阶段(2742例病例和51438例对照)鉴定出位于SOD2附近的新全基因组显著变异rs17186366(OR=1.37 [1.23, 1.54],P=2.8×10-8),并在验证阶段(253例病例和2161例对照)得到验证。此外还发现ERBB4和WWTR1的提示性关联,并验证了DENND1A1的已知关联。

要点

  • 基于鹿特丹标准的EHR表型算法可有效识别PCOS病例进行遗传研究。
  • SOD2附近变异rs17186366与PCOS全基因组显著关联并经独立验证。
  • ERBB4和WWTR1变异分别与月经稀发/不孕相关,提示EGFR和Hippo通路参与PCOS病因。

核心结论

  • 在基于鹿特丹标准的EHR识别PCOS的全基因组关联研究中,发现并验证了SOD2附近的新全基因组显著变异rs17186366。
  • 还发现了ERBB4内的新独立变异和WWTR1的提示性关联,ERBB4-YAP1-WWTR1网络提示EGFR和Hippo通路参与PCOS的多因素病因。

研究设计与样本

  • 研究基于鹿特丹标准开发PCOS表型算法,应用于3个电子健康记录链接的生物库。
  • 发现阶段使用Geisinger MyCode和Electronic Medical Records and Genomics队列进行个体GWAS并荟萃分析,验证阶段在BioVU队列中进行。
  • 关联分析采用逻辑回归(加性遗传模型),调整主成分以控制群体分层,荟萃分析采用逆方差固定效应模型。
  • 共识别2995例PCOS患者和53599例人群对照(发现阶段2742例病例和51438例对照;验证阶段253例病例和2161例对照)。

主要发现

  • 发现1个新的全基因组显著变异rs17186366(OR=1.37 [1.23, 1.54],P=2.8×10-8),位于SOD2附近。
  • 发现2个提示性关联位点:rs113168128(OR=1.72 [1.42, 2.10],P=5.2×10-8),为ERBB4的内含子变异,独立于已发表变异;rs144248326(OR=2.13 [1.52, 2.86],P=8.45×10-7),为WWTR1的新内含子变异。
  • rs17186366(SOD2)与多囊卵巢和高雄激素症相关,rs11316812(ERBB4)和rs144248326(WWTR1)主要与月经稀发或不孕相关。
  • 验证了DENND1A1的既往报道关联。
  • STRING数据库分析显示ERBB4和WWTR1均可与YAP1相互作用,YAP1此前已与PCOS关联。

关键数值与推荐

  • 全基因组显著性阈值P<1×10-6用于选择验证位点。
  • PCOS表型算法基于鹿特丹标准。

临床怎么用

  • EHR结合鹿特丹标准的表型算法可用于PCOS的大规模遗传研究。
  • SOD2、ERBB4、WWTR1等位点可能为PCOS的遗传机制提供线索,但尚未直接用于临床诊断或治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polycystic ovary syndrome is the most common endocrine disorder affecting women of reproductive age. A number of criteria have been developed for clinical diagnosis of polycystic ovary syndrome, with the Rotterdam criteria being the most inclusive. Evidence suggests that polycystic ovary syndrome is significantly heritable, and previous studies have identified genetic variants associated with polycystic ovary syndrome diagnosed using different criteria. The widely adopted electronic health record system provides an opportunity to identify patients with polycystic ovary syndrome using the Rotterdam criteria for genetic studies. OBJECTIVE: To identify novel associated genetic variants under the same phenotype definition, we extracted polycystic ovary syndrome cases and unaffected controls based on the Rotterdam criteria from the electronic health records and performed a discovery-validation genome-wide association study. STUDY DESIGN: We developed a polycystic ovary syndrome phenotyping algorithm on the basis of the Rotterdam criteria and applied it to 3 electronic health record-linked biobanks to identify cases and controls for genetic study. In the discovery phase, we performed an individual genome-wide association study using the Geisinger MyCode and the Electronic Medical Records and Genomics cohorts, which were then meta-analyzed. We attempted validation of the significant association loci (P<1×10-6) in the BioVU cohort. All association analyses used logistic regression, assuming an additive genetic model, and adjusted for principal components to control for population stratification. An inverse-variance fixed-effect model was adopted for meta-analysis. In addition, we examined the top variants to evaluate their associations with each criterion in the phenotyping algorithm. We used the STRING database to characterize protein-protein interaction network. RESULTS: Using the same algorithm based on the Rotterdam criteria, we identified 2995 patients with polycystic ovary syndrome and 53,599 population controls in total (2742 cases and 51,438 controls from the discovery phase; 253 cases and 2161 controls in the validation phase). We identified 1 novel genome-wide significant variant rs17186366 (odds ratio [OR]=1.37 [1.23, 1.54], P=2.8×10-8) located near SOD2. In addition, 2 loci with suggestive association were also identified: rs113168128 (OR=1.72 [1.42, 2.10], P=5.2×10-8), an intronic variant of ERBB4 that is independent from the previously published variants, and rs144248326 (OR=2.13 [1.52, 2.86], P=8.45×10-7), a novel intronic variant in WWTR1. In the further association tests of the top 3 single-nucleotide polymorphisms with each criterion in the polycystic ovary syndrome algorithm, we found that rs17186366 (SOD2) was associated with polycystic ovaries and hyperandrogenism, whereas rs11316812 (ERBB4) and rs144248326 (WWTR1) were mainly associated with oligomenorrhea or infertility. We also validated the previously reported association with DENND1A1. Using the STRING database to characterize protein-protein interactions, we found both ERBB4 and WWTR1 can interact with YAP1, which has been previously associated with polycystic ovary syndrome. CONCLUSION: Through a discovery-validation genome-wide association study on polycystic ovary syndrome identified from electronic health records using an algorithm based on Rotterdam criteria, we identified and validated a novel genome-wide significant association with a variant near SOD2. We also identified a novel independent variant within ERBB4 and a suggestive association with WWTR1. With previously identified polycystic ovary syndrome gene YAP1, the ERBB4-YAP1-WWTR1 network suggests involvement of the epidermal growth factor receptor and the Hippo pathway in the multifactorial etiology of polycystic ovary syndrome.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Ho K, Keaton JM, et al. A genome-wide association study of polycystic ovary syndrome identified from electronic health records. Am J Obstet Gynecol. 2020. PMID: 32289280. doi:10.1016/j.ajog.2020.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。